(Q71692478)
Statements
CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies (English)
Mavroudis D
Read E
Cottler-Fox M
Couriel D
Molldrem J
Carter C
Yu M